Your browser doesn't support javascript.
loading
Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology.
Little, Ross A; Jamin, Yann; Boult, Jessica K R; Naish, Josephine H; Watson, Yvonne; Cheung, Susan; Holliday, Katherine F; Lu, Huiqi; McHugh, Damien J; Irlam, Joely; West, Catharine M L; Betts, Guy N; Ashton, Garry; Reynolds, Andrew R; Maddineni, Satish; Clarke, Noel W; Parker, Geoff J M; Waterton, John C; Robinson, Simon P; O'Connor, James P B.
Afiliação
  • Little RA; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Jamin Y; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Boult JKR; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Naish JH; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Watson Y; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Cheung S; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Holliday KF; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Lu H; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • McHugh DJ; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Irlam J; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • West CML; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Betts GN; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Ashton G; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Reynolds AR; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Maddineni S; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Clarke NW; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Parker GJM; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Waterton JC; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • Robinson SP; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
  • O'Connor JPB; From the Centre for Imaging Sciences (R.A.L., J.H.N., Y.W., S.C., K.F.H., H.L., D.J.M., G.J.M.P., J.C.W.) and Division of Cancer Sciences (J.I., C.M.L.W., N.W.C., J.P.B.O.), University of Manchester, Manchester, England; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London,
Radiology ; 288(3): 739-747, 2018 09.
Article em En | MEDLINE | ID: mdl-29869970
ABSTRACT
Purpose To cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of tumor hypoxia with intrinsic susceptibility MRI measurements and to demonstrate the feasibility of translation of the technique for patients. Materials and Methods Preclinical studies in nine 786-0-R renal cell carcinoma (RCC) xenografts and prospective clinical studies in eight patients with RCC were performed. Longitudinal relaxation rate changes (∆R1) after 100% oxygen inhalation were quantified, reflecting the paramagnetic effect on tissue protons because of the presence of molecular oxygen. Native transverse relaxation rate (R2*) and oxygen-induced R2* change (∆R2*) were measured, reflecting presence of deoxygenated hemoglobin molecules. Median and voxel-wise values of ∆R1 were compared with values of R2* and ∆R2*. Tumor regions with dynamic contrast agent-enhanced MRI perfusion, refractory to signal change at OE MRI (referred to as perfused Oxy-R), were distinguished from perfused oxygen-enhancing (perfused Oxy-E) and nonperfused regions. R2* and ∆R2* values in each tumor subregion were compared by using one-way analysis of variance. Results Tumor-wise and voxel-wise ∆R1 and ∆R2* comparisons did not show correlative relationships. In xenografts, parcellation analysis revealed that perfused Oxy-R regions had faster native R2* (102.4 sec-1 vs 81.7 sec-1) and greater negative ∆R2* (-22.9 sec-1 vs -5.4 sec-1), compared with perfused Oxy-E and nonperfused subregions (all P < .001), respectively. Similar findings were present in human tumors (P < .001). Further, perfused Oxy-R helped identify tumor hypoxia, measured at pathologic analysis, in both xenografts (P = .002) and human tumors (P = .003). Conclusion Intrinsic susceptibility biomarkers provide cross validation of the OE MRI biomarker perfused Oxy-R. Consistent relationship to pathologic analyses was found in xenografts and human tumors, demonstrating biomarker translation. Published under a CC BY 4.0 license. Online supplemental material is available for this article.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Aumento da Imagem / Carcinoma de Células Renais / Neoplasias Renais / Hipóxia Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Aumento da Imagem / Carcinoma de Células Renais / Neoplasias Renais / Hipóxia Idioma: En Ano de publicação: 2018 Tipo de documento: Article